Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer

International Journal of Molecular Medicine

Volumn 26, Issue 6, 2010, Pages 837-843

  Gevensleben, Heidrun ^a   Göhring, Uwe Jochen ^b   Büttner, Reinhard ^a   Heukamp, Lukas C ^a   Kunz, Georg ^c   Dimpfl, Thomas ^d   Jackisch, Christian ^e   Ortmann, Olaf ^f   Albert, Ute Susann ^g   Bender, Richard ^h   De Snoo, Femke ⁱ   Krijgsman, Oscar ⁱ   Glas, Annuska M ⁱ   Ergönenc, Yavuz H ^j   Vogel, Corinna ^k   Dykgers, August ^l   Langwieder, Claus ^l   Rees, Martin ^l   Anzeneder, Tobias ^m  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Johanniter Krankenhaus   (Germany)

^c ST JOHANNES HOSPITAL   (Germany)

^d KLINIKUM KASSEL   (Germany)

^e Klinikum Offenbach GmbH   (Germany)

^f UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

^h Agendia Inc   (United States)

ⁱ Agendia NV   (Netherlands)

^j ST ANNA HOSPITAL   (Germany)

^k UNIVERSITY OF REGENSBURG   (Germany)

^l Institute of Pathology at Josefshaus   (Germany)

^m Patients Tumor Bank of Hope   (Germany)

more..

Author keywords

70 gene expression profile; Adjuvant therapy; Breast cancer; MammaPrint; Microarray; TargetPrint

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC TEST; EARLY CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GERMAN DEMOCRATIC REPUBLIC; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMAPRINT; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TARGETPRINT; VALIDITY;

EID: 78649960543     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000532     Document Type: Article

References (27)

1. EBCTCG: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
2. EBCTCG: Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352: 930-942, 1998. (Pubitemid 28427277)
3. EBCTCG: Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451-1467, 1998.
4. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
5. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al: Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 8: 1079-1087, 2007.
6. Buyse M, Loi S, van't Veer L, et al: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98: 1183-1192, 2006.
7. Mook S, Schmidt MK, Viale G, et al: The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116: 295-302, 2009.
8. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002.
9. Wittner BS, Sgroi DC, Ryan PD, et al: Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 14: 2988-2993, 2008.
10. Mook S, et al: The 70-gene MammaPrint prognosis signature predicts early metastases in older breast cancer patients. Ann Oncol 21: 717-722, 2010.
11. Glas AM, Floore A, Delahaye LJ, et al: Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7: 278, 2006.
12. Bogaerts J, Cardoso F, Buyse M, et al: Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 3: 540-551, 2006.
13. Thomson TA, Hayes MM, Spinelli JJ, et al: HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 14: 1079-1086, 2001.
14. Regitnig P, Reiner A, Dinges HP, et al: Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 441: 328-334, 2002.
15. Roepman P: Microarray based determination of ER, PR and HER2 receptor status in breast cancer. Clin Cancer Res (In press).
16. Michiels S, Koscielny S and Hill C: Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365: 488-492, 2005. (Pubitemid 40215731)
17. Ransohoff DF: Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4: 309-314, 2004.
18. Simon R, Radmacher MD, Dobbin K and McShane LM: Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95: 14-18, 2003. (Pubitemid 36124291)
19. Eden P, Ritz C, Rose C, Ferno M and Peterson C: 'Good Old' clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40: 1837-1841, 2004.
20. Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20: 3628-3636, 2002.
21. Todd JH, Dowle C, Williams MR, et al: Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56: 489-492, 1987. (Pubitemid 17146357)
22. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
23. Hauser-Kronberger C and Dandachi N: Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol 35: 647-653, 2004.
24. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357-3365, 2003. (Pubitemid 46606270)
25. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19: 980-991, 2001.
26. Olivotto IA, Bajdik CD, Ravdin PM, et al: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23: 2716-2725, 2005.
27. Bueno-de-Mesquita JM, Linn SC, Keijzer R, et al: Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 117: 483-495, 2009.